American Journal of Cardiology
Volume 103, Issue 12 , Pages 1694-1702 , 15 June 2009

Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Versus Atorvastatin in Patients With Hypercholesterolemia and the Metabolic Syndrome (from the VYMET Study)

  • Jennifer G. Robinson, MD, MPH

      Affiliations

    • University of Iowa College of Public Health, Iowa City, Iowa
    • Corresponding Author InformationCorresponding author: Tel: (319) 384-5040; fax: (319) 384-5004
    • ,
  • Christie M. Ballantyne, MD

      Affiliations

    • Baylor College of Medicine and Methodist DeBakey Heart and Vascular Center, Houston, Texas
    • ,
  • Scott M. Grundy, MD, PhD

      Affiliations

    • University of Texas Southwestern Medical Center at Dallas, Dallas, Texas
    • ,
  • Willa A. Hsueh, MD

      Affiliations

    • Methodist Hospital Research Institute, Houston, Texas
    • ,
  • Hans-Henrik Parving, MD

      Affiliations

    • Department of Medical Endocrinology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark
    • ,
  • Jeffrey B. Rosen, MD

      Affiliations

    • Clinical Research of South Florida, Coral Gables, Florida
    • ,
  • Adeniyi J. Adewale, PhD

      Affiliations

    • Merck & Company, Incorporated, North Wales, Pennsylvania
    • ,
  • Adam B. Polis, MA

      Affiliations

    • Merck & Company, Incorporated, North Wales, Pennsylvania
    • ,
  • Joanne E. Tomassini, PhD

      Affiliations

    • Merck & Company, Incorporated, North Wales, Pennsylvania
    • ,
  • Andrew M. Tershakovec, MD, MPH

      Affiliations

    • Merck & Company, Incorporated, North Wales, Pennsylvania

Received 31 March 2009 ,Revised 7 May 2009 ,Accepted 7 May 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This study was funded by Merck/Schering-Plough Pharmaceuticals, North Wales, Pennsylvania; the study sponsor, Merck & Company, Incorporated, Whitehouse Station, New Jersey, facilitated the design and conduct of the study and the collection and analysis of the study data.

 Dr. Robinson received research support from AstraZeneca, Abbott, Aegerion, Bristol-Meyers Squibb, Hoffman LaRoche, Merck, and Merck/Schering-Plough Pharmaceuticals; honoraria from Merck/Schering-Plough Pharmaceuticals; and has served as a consultant and/or member of an advisory board for Merck/Schering-Plough Pharmaceuticals. Dr. Ballantyne received research support from Abbott, AstraZeneca, GSK, Merck, Pfizer, Sanofi-Synthelabo, Schering-Plough, and Takeda; has served on the Speakers' Bureau of AstraZeneca, GSK, Merck, Merck/Schering-Plough Pharmaceuticals, Pfizer, Reliant, and Schering-Plough; has received honoraria from AstraZeneca, Merck, Abbott, Atherogenics, GSK, Merck/Schering-Plough Pharmaceuticals, Novartis, Pfizer, Sanofi-Synthelabo, Schering-Plough, and Takeda; and has served as a consultant or advisory board member for Abbott, AstraZeneca, Atherogenics, GSK, Merck, Merck/Schering-Plough Pharmaceuticals, Novartis, Pfizer, Sanofi-Synthelabo, Schering-Plough, and Takeda. Dr. Grundy received honoraria from Merck/Schering-Plough Pharmaceuticals and served as a consultant and/or advisory board member for Merck, Merck/Schering-Plough Pharmaceuticals, AstraZeneca, Pfizer, and GSK. Dr. Hsueh received honoraria from Merck/Schering-Plough Pharmaceuticals and served on the Speakers' Bureau of Merck/Schering-Plough Pharmaceuticals and GSK; and served as a consultant or member of the advisory board for Novartis and Daiicho Sankyo. Dr. Parving received honoraria from Merck/Schering-Plough Pharmaceuticals. Dr. Rosen received research support from Roche, GSK, and Sankyo; and has received honoraria from Merck/Schering-Plough Pharmaceuticals. Drs. Adewale, Tershakovec, and Tomassini and Mr. Polis are employees of Merck & Company, Incorporated, and own stock and/or stock options in the company.

PII: S0002-9149(09)01026-1

doi: 10.1016/j.amjcard.2009.05.003

American Journal of Cardiology
Volume 103, Issue 12 , Pages 1694-1702 , 15 June 2009

Article Tools

* Image Usage & Resolution